Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

CLASS ACTION UPDATE for OLO, CNTA and IGT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

10:00 pm ET November 21, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 21, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OLO Shareholders Click Here: https://www.zlk.com/pslra-1/olo-inc-loss-submission-form?prid=33938&wire=1

CNTA Shareholders Click Here: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=33938&wire=1

IGT Shareholders Click Here: https://www.zlk.com/pslra-1/igt-lawsuit-submission-form?prid=33938&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Monday, November 21, 2022, Press release picture

Olo Inc. (NYSE:OLO)

This lawsuit is on behalf of all persons and entities that purchased shares of Olo's Class A common stock between August 11, 2021 and August 11, 2022.

Lead Plaintiff Deadline : November 28, 2022

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olo-inc-loss-submission-form?prid=33938&wire=1

According to the filed complaint, (1) Subway was ending its contract with Olo; (2) Olo's key business metric - active locations - could not continue to grow as defendants touted due to the loss of Subway's business; and (3) as a result of the above, defendants' statements about Olo's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Centessa Pharmaceuticals plc (NASDAQ:CNTA)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.

Lead Plaintiff Deadline : November 28, 2022

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=33938&wire=1

According to the filed complaint, (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

International Game Technology PLC (NYSE:IGT)

IGT Lawsuit on behalf of: investors who purchased March 16, 2018 - August 29, 2022

Lead Plaintiff Deadline : December 13, 2022

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/igt-lawsuit-submission-form?prid=33938&wire=1

According to the filed complaint, during the class period, International Game Technology PLC made materially false and/or misleading statements and/or failed to disclose that: (i) IGT overstated its compliance with gaming and lottery laws and applicable regulations; (ii) IGT and/or one or more of its current and/or former subsidiaries engaged in illegal gambling operations; (iii) the foregoing conduct subjected the Company and/or its current and/or former subsidiaries to a heightened risk of litigation and significant related costs; (iv) the Company downplayed the full scope and severity of its financial exposure to, and/or liabilities in connection with, the lawsuit filed against IGT's subsidiary in April of 2018; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP





View source version on accesswire.com:

https://www.accesswire.com/727680/CLASS-ACTION-UPDATE-for-OLO-CNTA-and-IGT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



comtex tracking

COMTEX_419448167/2457/2022-11-21T22:00:30

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.